# GI Innovation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gi-innovation

- Industry: Pharmaceuticals
- Headquarters: Seoul, South Korea
- Website: www.gi-innovation.com
- Total disclosed funding: $72M
- Latest round: Series C (Mar 13, 2020)
- Investors on record: 15

## About

Based in Seoul, South Korea and founded in 2017, GI Innovation, Inc. operates as a bio-venture company that develops treatments for immuno-oncology, inflammation, and immunology diseases. GI Innovation Co., Ltd. has established GI-SMART™ platform technology that is designed to accelerate the development of biologics through the optimization of multi-targeting fusion protein therapeutics with high quality and high productivity. GI Innovation, Inc. has been certified by the International Standard Information Protection in 2021. In June 2021, GI Innovation Co., Ltd. raised KRW 160.3 billion in pre-IPO funding from investors DS Asset Management, iMarket Korea, Yuhan Corporation, Brain Asset Management, Genexine, Inc., NH Investment & Securities, and SK Group.

The company's platform technology GI-SMART™ is being used to develop its projects on multi-targeting fusion protein therapeutics namely; GI-101, GI-301, GI-10N, GI-30, and GI-20N.

GI Innovation, Inc.'s main pipeline is GI-101, an immuno-cancer drug, and GI-301, an allergy treatment, produced using its own platform, and GI-SMART technology. The company gained KRW 900 billion worth through the technology transfer of GI-101 to Simcere, one of China's top 10 innovative pharmaceutical companies in 2019. Furthermore, in 2020, the GI-301 pipeline was transferred to Yuhan Corporation for KRW 1.4 trillion.

GI Innovation, Inc., which is pursuing a special listing for its growth potential, plans to submit a request for a preliminary examination on the KOSDAQ and initiate an IPO (public disclosure) in the first half of 2021.

## Funding rounds

- Series C, Mar 13, 2020, $25M — Mirae Asset Venture Investment, NH Investment & Securities, KClavis Investment
- Series B, Aug 10, 2019, $31M — AJU IB Investment, Meritz Securities, NH Investment & Securities, Samsung Securities, Time Folio Asset Management, Hana Securities, DAYLI Partners, DS & Partners, Mirae Asset Securities, Yuhan Corporation, KClavis Investment, DS Asset Management
- Series A, Oct 12, 2018, $16M — Korea Development Bank, DAYLI Partners, KClavis Investment, ST Capital

## Investors

- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series A
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series A, Series B
- KClavis Investment (https://capitalatlas.ai/funds/kclavis-investment) — Series A, Series B, Series C
- ST Capital (https://capitalatlas.ai/funds/st-capital) — Series A
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series B
- Meritz Securities — Series B
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series B, Series C
- Samsung Securities — Series B
- Time Folio Asset Management — Series B
- Hana Securities (https://capitalatlas.ai/funds/hana-securities) — Series B
- DS & Partners (https://capitalatlas.ai/funds/ds-partners) — Series B
- Mirae Asset Securities (https://capitalatlas.ai/funds/mirae-asset-securities) — Series B
- Yuhan Corporation — Series B
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series B
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series C